Logo
x

Search

Subscribe Now

EMDAC

The US FDA's EMDAC Supports Provention Bio's Teplizumab in Delaying Diabetes

The US FDA's EMDAC Supports Provention Bio's Teplizumab in Delaying Diabetes

  • May 28, 2021
Boehringer Ingelheim and Lilly Report FDA's EMDAC Outcomes for Empagliflozin (2.5mg) as Adjunct to Insulin for T1D Patients

Boehringer Ingelheim and Lilly Report FDA's EMDAC Outcomes for Empagliflozin (2.5mg) as Adjunct to Insulin for T1D Patients

  • November 14, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.